These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma. Jiang H; Yu K; Cui Y; Ren X; Li M; Zhang G; Yang C; Zhao X; Zhu Q; Lin S Front Oncol; 2021; 11():632663. PubMed ID: 34055603 [TBL] [Abstract][Full Text] [Related]
5. DNA methylation profiles of long- and short-term glioblastoma survivors. Shinawi T; Hill VK; Krex D; Schackert G; Gentle D; Morris MR; Wei W; Cruickshank G; Maher ER; Latif F Epigenetics; 2013 Feb; 8(2):149-56. PubMed ID: 23291739 [TBL] [Abstract][Full Text] [Related]
6. Comprehensive molecular characterization of long-term glioblastoma survivors. Xu H; Chen X; Sun Y; Hu X; Zhang X; Wang Y; Tang Q; Zhu Q; Song K; Chen H; Sheng X; Yao Y; Zhuang D; Chen L; Mao Y; Qin Z Cancer Lett; 2024 Jul; 593():216938. PubMed ID: 38734160 [TBL] [Abstract][Full Text] [Related]
7. IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients. Amelot A; De Cremoux P; Quillien V; Polivka M; Adle-Biassette H; Lehmann-Che J; Françoise L; Carpentier AF; George B; Mandonnet E; Froelich S PLoS One; 2015; 10(7):e0130596. PubMed ID: 26158269 [TBL] [Abstract][Full Text] [Related]
8. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M; Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of Lam K; Eldred BSC; Kevan B; Pianka S; Eldred BA; Zapanta Rinonos S; Yong WH; Liau LM; Nghiemphu PL; Cloughesy TF; Green RM; Lai A Neurooncol Adv; 2022; 4(1):vdac030. PubMed ID: 35386566 [TBL] [Abstract][Full Text] [Related]
17. Analysis of Factors Associated with Long-Term Survival in Patients with Glioblastoma. Madhugiri VS; Moiyadi AV; Shetty P; Gupta T; Epari S; Jalali R; Subeikshanan V; Dutt A; Sasidharan GM; Roopesh Kumar VR; Shankar Ganesh CV; Ramesh AS; Sathia Prabhu A World Neurosurg; 2021 May; 149():e758-e765. PubMed ID: 33540096 [TBL] [Abstract][Full Text] [Related]
18. Genome-wide DNA methylation profiling identifies ALDH1A3 promoter methylation as a prognostic predictor in G-CIMP- primary glioblastoma. Zhang W; Yan W; You G; Bao Z; Wang Y; Liu Y; You Y; Jiang T Cancer Lett; 2013 Jan; 328(1):120-5. PubMed ID: 22960273 [TBL] [Abstract][Full Text] [Related]
19. [Analyses of IDH1 mutation and MGMT promoter methylation status for 5 cases of long-term survivors with glioblastoma]. Kamoshima Y; Motegi H; Terasaka S; Kobayashi H; Yamaguchi S; Murata J; Tanaka S; Houkin K No Shinkei Geka; 2012 Feb; 40(2):129-35. PubMed ID: 22281465 [TBL] [Abstract][Full Text] [Related]
20. MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value. Leske H; Camenisch Gross U; Hofer S; Neidert MC; Leske S; Weller M; Lehnick D; Rushing EJ Acta Neuropathol Commun; 2023 Aug; 11(1):139. PubMed ID: 37641156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]